<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108625</url>
  </required_header>
  <id_info>
    <org_study_id>12712B</org_study_id>
    <secondary_id>2015-002658-11</secondary_id>
    <nct_id>NCT03108625</nct_id>
  </id_info>
  <brief_title>Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age</brief_title>
  <official_title>Long-term, Open-label, Flexible-dose, Continuation Extension Study With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent
      patients with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™)
      diagnosis of MDD
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety)</measure>
    <time_frame>Up to Week 104</time_frame>
    <description>Based on safety assessments (e.g. paediatric adverse event rating scale (PAERS), clinical safety laboratory tests (including reproductive hormones), vital signs, weight, height, Tanner score, menstrual cycle, ECG, and C-SSRS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in CDRS-R total score</measure>
    <time_frame>Change from study 12712A baseline to Week 104</time_frame>
    <description>Children Depression Rating Scale, revised version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapses (CDRS-R ≥40 with a history of 2 weeks of clinical deterioration)</measure>
    <time_frame>Up to Week 104</time_frame>
    <description>Number of relapses (CDRS-R ≥40 with a history of 2 weeks of clinical deterioration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss of remission (CDRS-R &lt;28 with a history of 2 weeks of clinical deterioration)</measure>
    <time_frame>Up to Week 104</time_frame>
    <description>Loss of remission (CDRS-R &lt;28 with a history of 2 weeks of clinical deterioration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CGI-S score</measure>
    <time_frame>Change from study 12712A baseline to Week 104</time_frame>
    <description>Clinical Global Impression - Severity of Illness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-I score</measure>
    <time_frame>Week 104</time_frame>
    <description>Clinical Global Impression - Global Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children (7-11 years): change in BRIEF using the Global Executive Composite score</measure>
    <time_frame>Change from study 12712A baseline to Week 104</time_frame>
    <description>Behaviour Rating Inventory of Executive Function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children (7-11 years): change in BRIEF using the Megacognition Index</measure>
    <time_frame>Change from study 12712A baseline to Week 104</time_frame>
    <description>Behaviour Rating Inventory of Executive Function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adolescents (12-17 years): change in BRIEF-SR using the Global Executive Composite score</measure>
    <time_frame>Change from study 12712A baseline to Week 104</time_frame>
    <description>Behaviour Rating Inventory of Executive Function, Self-report version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adolescents (12-17 years): change in BRIEF-SR using the Megacognition Index</measure>
    <time_frame>Change from study 12712A baseline to Week 104</time_frame>
    <description>Behaviour Rating Inventory of Executive Function, Self-report version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CGAS score</measure>
    <time_frame>Change from study 12712A baseline to Week 104</time_frame>
    <description>Children's Global Assessment Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PedsQL VAS score</measure>
    <time_frame>Change from study 12712A baseline to Week 104</time_frame>
    <description>Pediatric Quality of Life Inventory Present Functioning Visual Analogue Scales</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>Vortioxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily dosing of vortioxetine (oral tablets) for 78 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine</intervention_name>
    <description>Target dose is 10 mg/day; the dose can be down- or uptitrated to 5, 15, or 20 mg/day.</description>
    <arm_group_label>Vortioxetine</arm_group_label>
    <other_name>Brintellix</other_name>
    <other_name>Lu AA21004</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is a male or female child aged ≥7 and &lt;12 years or an adolescent aged ≥12
             and ≤17 years at Baseline in Study 12712B.

          -  The patient must have completed extension Study 12712A immediately prior to enrolment
             into this extension study.

          -  The patient had a primary diagnosis of a MDD at entry in Study 12709A or 12710A,
             diagnosed according to DSM-5™.

          -  The patient is still indicated for long-term treatment with vortioxetine according to
             the clinical opinion of the investigator.

        Exclusion Criteria:

          -  The patient has been diagnosed with another psychiatric disorder (for example mania,
             bipolar disorder, schizophrenia or any psychotic disorder) during study 12712A.

          -  The patient has an attention-deficit/hyperactivity disorder (ADHD) that requires a
             pharmacological treatment other than a stimulant medication.

        Other protocol-defined inclusion and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MHAT &quot;Targovishte&quot; AD</name>
      <address>
        <city>Targovishte</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCC Mladost-M</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienthal Center of Psychiatry and Psychology</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Psyche</name>
      <address>
        <city>Douai</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Medical Ambroise Pare</name>
      <address>
        <city>Élancourt</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheinhessen-Fachklinik Mainz, Kinder und Jugendpsychiatri</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vadaskert Alapitvany</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Trust-University of Cagliari</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Messina - Facolta di Medicina e Chirurgia</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Gintermuiza&quot;</name>
      <address>
        <city>Jelgava</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linda Keruze's Psychiatric Center, LLC</name>
      <address>
        <city>Liepāja</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children Hospital - Gailezers</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatne Gabinety Lekarskie ¿Promedicus¿ Anna Agnieszka Tomczak</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych PI-House Sp. z o.o.</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Przychodnia Syntonia Poradnia Zdrowia Psychicznego</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPECTRUM Centrum Neurologii i Psychiatrii</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Filip Rybakowski Specjalistyczna Praktyka Lekarska</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zaklad Opieki Zdrowotnej (SPZOZ) - Centrum Neuropsychiatrii &quot;NEUROMED&quot;</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of Sverdlovsk Region</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizhny Novgorod Region State Institution Of Healthcare</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guz &quot;Saratov Regional Psychiatric Hospital St. Sofii&quot;</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saratov State Medical University</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution</name>
      <address>
        <city>Tonnel'nyy</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Neurology and Psychiatry for Children and Adolescents</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Vojvodina - Clinic of Psychiatry</name>
      <address>
        <city>Novi Sad</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cape Trial Centre</name>
      <address>
        <city>Bellville</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Alcorcon</name>
      <address>
        <city>Alcorcón</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Salud Mental Infanto-Juvenil (USMI-J) Edificio de Consultas Externas. Hospital MarAtimo</name>
      <address>
        <city>Torremolinos</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>children</keyword>
  <keyword>adolescent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vortioxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

